Press Releases

Press Releases

Apr 21, 2021	Ionis to hold first quarter 2021 financial results webcast
Apr 20, 2021	Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
Apr 08, 2021	Ionis prices private placement of convertible senior notes
Apr 06, 2021	Ionis announces proposed private placement of convertible notes
Apr 05, 2021	Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Mar 29, 2021	Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Mar 26, 2021	Ionis to present at upcoming investor conferences
Mar 22, 2021	Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
Mar 01, 2021	Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
Feb 24, 2021	Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
Feb 19, 2021	Ionis to present at upcoming investor conferences
Feb 11, 2021	Ionis to hold 2020 financial results webcast
Jan 07, 2021	Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Jan 05, 2021	Ionis to present at 39th Annual J.P. Morgan Healthcare Conference

Investor contact